SCHEMBL10110849

SCHEMBL10110849

CN(CCCNC(=O)CCCCC1SCC2NC(=O)NC21)CCCNC(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.59
▸ CA12 O43570 2/20 0.53
▸ CA1 P00915 2/20 0.53
▸ CA2 P00918 2/20 0.53
▸ CA9 Q16790 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ ABL1 P00519 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ IDE P14735 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ RIN1 Q13671 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ F2 P00734 1/20 0.51
▸ PRSS1 P07477 1/20 0.51
▸ PRSS2 P07478 1/20 0.51
▸ PRSS3 P35030 1/20 0.51
▸ TPSAB1 Q15661 1/20 0.51
▸ CAPN1 P07384 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13682823 0.90 TDP1 (0.60) TDP1CA12CA1CA2CA9
SCHEMBL16602265 0.89 TDP1 (0.62) TDP1CA12CA1CA2CA9
SCHEMBL18474173 0.87 TDP1 (0.67) TDP1CA12CA1CA2CA9
SCHEMBL23074579 0.86 TDP1 (0.60) TDP1CA12CA1CA2CA9
SCHEMBL10110857 0.84 F2 (0.65) TDP1CA12CA1CA2CA9
SCHEMBL18025039 0.84 F2 (0.67) TDP1CA12CA1CA2CA9
SCHEMBL10110855 0.84 F2 (0.67) TDP1CA12CA1CA2CA9
SCHEMBL17031589 0.83 TDP1 (0.57) TDP1CA12CA1CA2CA9
SCHEMBL21340482 0.83 TDP1 (0.67) TDP1CA12CA1CA2CA9
SCHEMBL18874899 0.83 TDP1 (0.72) TDP1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9333232-B2 Methods for treating papilloma virus infection NANOVIR LLC (US) 2016-05-10 — — US disclosed
US-8119677-B2 Polyamides containing amino butyric acid-based building blocks NANOVIR, LLC (US) 2012-02-21 — — US disclosed
US-20100015084-A1 Compounds for Treating Papilloma Virus Infection NANOVIR, LLC (US) 2010-01-21 — — US disclosed
US-20090306164-A1 Methods for Treating Papilloma Virus Infection NANOVIR, LLC (US) 2009-12-10 — — US disclosed
US-20090306164-A1 Methods for Treating Papilloma Virus Infection NANOVIR, LLC (US) 2009-12-10 — — US disclosed
US-7589171-B2 Polyamides for treating human papilloma virus NANOVIR, LLC (US) 2009-09-15 — — US disclosed
US-20070293417-A1 Polyamides for treating human papilloma virus NANOVIR, LLC 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306164-A1 Methods for Treating Papilloma Virus Infection POLI, VHL, TLR3 TDP1 4204/4885CA12 45/4885CA1 627/4885
US-20100015084-A1 Compounds for Treating Papilloma Virus Infection POLI, PMAIP1, TLR3 TDP1 3369/4885CA12 285/4885CA1 2521/4885
US-20070293417-A1 Polyamides for treating human papilloma virus POLI, PARG, PARN TDP1 1709/4885CA12 332/4885CA1 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback